TAILIEUCHUNG - Clinical outcome of pembrolizumab for various malignancies in single institute in Vietnam

Pembolizumabis an immune check-point inhibitor to be targeted for Programmed cell death 1 (PD-1). It has been shown promising efficacy to various types of cancer. In Vietnam, pembrolizumab has been available since early of 2018. We has performed to treat certain types of cancer with pembrolizumabby now, herein we report the early experience with pembrolizumabin single institute in Vietnam. | Clinical outcome of pembrolizumab for various malignancies in single institute in Vietnam

TỪ KHÓA LIÊN QUAN